Predicine L-P WGS

Low-pass whole genome sequencing for comprehensive coverage of chromosomal abnormalities in cancer

• Whole genome-wide profiling 

• Measures tumor fraction

• Analyzes copy number variants

• Complementary approach to targeted deep sequencing panels for a broader view of the genomic landscape of tumors

Learn More
PredicineLPWGS

Features and benefits

High Sensitivity Predicine

2-3x coverage of the genome

15% LOD

Low Input of Predicine Assays

Complementary to targeted panels

CLIA Validated ATLAS

Liquid and tissue flexibility

Sample types

Whole blood
Plasma
Urine
FFPE

Sample requirements

10ml whole blood*
4ml plasma (down to 0.4ml)
40ml urine
10 FFPE slides

Turnaround time

10 days

Resources

Technical specifications

*CLIA-validated assay requires two tubes of 10mL blood

Unbiased and high-throughput copy number assessment

L-P WGS data combined with targeted deep sequencing panel from a single sample

Integrating whole-genome sequencing with targeted deep sequencing panels helps to provide a broader and comprehensive view of the genomic landscape in cancer.  The increasing information provided by L-P WGS  can be valuable for monitoring treatment response, detecting disease progression early, and identifying emergent clones associated with therapeutic resistance.  

 

LPWGS_Predicine

Longitudinal monitoring of prostate cancer using cfDNA

PredicineWGS on mCRPC

Workflow

PredicineATLAS workflow

Available in RUO and CLIA-validated assay

PILOT PROGRAM

We offer pilot program grants to select biopharma and academic partners to empower translational research and clinical studies. To initiate a study, contact us via the form below.

Contact us

If you have any questions or need assistance, complete this form and we will respond within 24 hours.

SEE OTHER TESTS